Track Neurocrine Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Neurocrine Biosciences, Inc. NBIX Open Neurocrine Biosciences, Inc. in new tab

131.60 USD
P/E
27.56
EPS
4.67
P/B
3.96
ROE
16.38
Beta
0.36
Target Price
178.04 USD
Neurocrine Biosciences, Inc. logo

Neurocrine Biosciences, Inc.

🧾 Earnings Recap – Q3 2025

Neurocrine Biosciences showcased robust performance in Q3 2025 with net product sales reaching $790 million, driven by strong growth in both INGREZZA and CRENESSITY as the company executes on its strategic initiatives.

  • Net sales increased 28% year-over-year, with INGREZZA contributing $687 million and CRENESSITY generating $98 million in its early launch phase.
  • Continued investments in expanding the sales force are aligned with projections for significant growth in the tardive dyskinesia market through 2029.
  • The company remains on track for its R&D productivity goals, with advancements in multiple Phase I and Phase II studies within its pipeline.
  • A planned $150 million increase in SG&A expenses for 2026 reflects a commitment to driving growth in both INGREZZA and CRENESSITY.
  • Neurocrine's financial position remains strong with over $2.1 billion in cash, underpinning future investments in innovation and shareholder returns.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
P/E27.56
EPS4.67
Book Value32.50
Price to Book3.96
Debt/Equity14.49
% Insiders1.106%
Growth
Revenue Growth0.28%
Earnings Growth0.48%
Estimates
Forward P/E13.24
Forward EPS9.72
Target Mean Price178.04

DCF Valuation

Tweak assumptions to recompute fair value for Neurocrine Biosciences, Inc. (NBIX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Neurocrine Biosciences, Inc. Logo Neurocrine Biosciences, Inc. Analysis (NBIX)

United States Health Care Official Website Stock

Is Neurocrine Biosciences, Inc. a good investment? Neurocrine Biosciences, Inc. (NBIX) is currently trading at 131.60 USD. Market analysts have a consensus price target of 178.04 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 27.56. This valuation is generally in line with the broader market.

Earnings Schedule: Neurocrine Biosciences, Inc. is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is 9.72.

Investor FAQ

Does Neurocrine Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of 4.67.

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) NBIX
LSE (United Kingdom) 0K6R.L
FRA (Germany) NB3.F
SAO (Brazil) N1BI34.SA

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion